Psychedelics
Coming soon
Psychedelic Therapeutics
Be notified when it is released.
Intelligence
Regulation, markets, pipeline status, and news signals across pharma, psychedelics, cannabis, and digital health — monitored from public sources and reviewed with editorial judgment.
How this is built →Selected FDA and DEA documents from the Federal Register, and clinical-trial registrations from ClinicalTrials.gov, kept apart. Documents show their publication date and registrations the date ClinicalTrials.gov first posted them.
FDA and DEA documents in the Federal Register. Dates shown are publication dates.
On August 5, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. The Department of Health and Human Services (HHS) provided the Drug Enforcement Administration…
Federal Register document 2026-23075
View on Federal RegisterNSI Lab Solutions LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Federal Register document 2026-23006
View on Federal RegisterThe Drug Enforcement Administration (DEA) proposes to establish the 2027 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine…
Federal Register document 2026-22843
View on Federal RegisterA registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works. Dates shown are first-posted dates.
Anxiety, Parenting Stress, Depressive Symptoms — ALMA-RN Instagram-Based Parental Education Programme
ClinicalTrials.gov registration NCT07943936 · first posted Nov 17, 2026
Status is as reported by ClinicalTrials.gov at the last verified check (Nov 17, 2026), not a real-time status.
A registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works.
View on ClinicalTrials.govPostpartum Depression, Postpartum Depression (PPD), Postnatal Depression — Forest Therapy Group, Standard Care (in control arm)
ClinicalTrials.gov registration NCT07943858 · first posted Nov 17, 2026
Status is as reported by ClinicalTrials.gov at the last verified check (Nov 17, 2026), not a real-time status.
A registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works.
View on ClinicalTrials.govLate Life Depression (LLD), MCI, MCI-AD, Early Stage Alzheimer's Disease — Ketamine and saline, Active Placebo (Midazolam) Infusion
ClinicalTrials.gov registration NCT07943741 · first posted Nov 17, 2026
Status is as reported by ClinicalTrials.gov at the last verified check (Nov 17, 2026), not a real-time status.
A registration is a sponsor’s listing of a study on ClinicalTrials.gov. It is not a regulatory action and does not show that a trial has results or that a treatment works.
View on ClinicalTrials.govTracked public-market securities, equities and ETFs, connected to behavioral health: pharma psychiatry, psychedelics, cannabis, and digital health. Open Markets for every tracked company's profile and Behavioral Wire's recent coverage of it.
Delayed quotes. Last updated 17 Nov 2026, 22:45 UTC.
Delayed quotes. Last updated 17 Nov 2026, 22:45 UTC.
Each dot is one indication mark (a program and one of its indications); the stage totals count tracks, and a track can cover two indications. Device and digital programs are authorized or cleared, not approved.
Open the Pipeline Map →Movement tracking since Oct 9, 2026; 90-day history covers 4 of 29 tracks.
All changes →Psychedelics
Coming soon
Be notified when it is released.
Structured records of regulatory and policy actions, built from primary government sources and organized around what changed, when decisions took effect, and what remains unresolved.
First product
Current corpus:U.S. Drug Enforcement Administration
Selected regulatory actions reconstructed from official government records, separating proposal, formal decision, effective date, correction, and unresolved status.
Scope
Selected Drug Enforcement Administration actions under the Controlled Substances Act, compiled from official Federal Register documents. Dates shown are those the documents themselves state. This is a curated record, not a complete account of DEA activity. Each record shows its status as of the date given. The linked Federal Register text controls.
8 records · status as of October 31, 2026
Current status Permanently placed in Schedule I; effective October 21, 2026.
Summary
In May 2026 DEA proposed placing diphenidine in Schedule I of the Controlled Substances Act. DEA finalized the permanent placement in a final rule published September 21, 2026. The final rule is effective October 21, 2026.
Regulatory sequence, oldest first
Notice of proposed rulemaking
What changedDEA opened a proposed rule. No legal change yet.
91 FR 30519 · Federal Register FR Doc. 2026-10380
Final rule
What changedDEA finalized permanent Schedule I placement.
Finalized from the proposed rule published May 26, 2026.
91 FR 59695 · Federal Register FR Doc. 2026-19231
The Schedule I placement took legal effect.
Established by 91 FR 59695 · Federal Register FR Doc. 2026-19231
How to cite
Behavioral Wire. “Diphenidine: Schedule I placement” (DEA-1155). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1155
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Current status DEA has made the final determination, but the change becomes effective November 9, 2026.
ImportantThis action does not schedule butalbital. It does not affect exempted prescription products with active National Drug Codes.
Summary
DEA is revoking the exempt status of certain nonnarcotic prescription products on its Table of Exempted Prescription Products whose National Drug Codes are inactive, because the products are no longer available and/or the company that applied for the exemption no longer exists. This action does not schedule butalbital. It does not affect exempted prescription products with active National Drug Codes. DEA signed the final determination October 6, 2026 and published it October 9, 2026; it takes effect November 9, 2026.
Regulatory sequence, oldest first
Notice of proposed rulemaking
What changedDEA proposed to revoke the exempt status of the specified products. No legal change yet.
91 FR 30527 · Federal Register FR Doc. 2026-10379
Final determination
What changedDEA determined that the exempt status of the specified products is revoked, effective November 9, 2026.
Finalized from the proposed rule; the determination cites 91 FR 30527.
91 FR 64618 · Federal Register FR Doc. 2026-20757
The revocation takes legal effect on this date.
Established by 91 FR 64618 · Federal Register FR Doc. 2026-20757
How to cite
Behavioral Wire. “Butalbital: removal of exempt status for inactive products” (DEA-1664). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1664
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Current status Temporary Schedule I placement remains in effect through August 12, 2028, unless extended or replaced through subsequent action.
Summary
In June 2026 DEA announced its intent to issue a temporary order placing O-desmethyltramadol (O-DSMT) in Schedule I. It issued the temporary order August 12, 2026, effective August 12, 2026 until August 12, 2028. A correcting amendment published October 9, 2026 restored omitted language concerning salts, isomers and salts of isomers in the CFR listing; it is not a new scheduling decision.
Regulatory sequence, oldest first
Notice of intent to issue a temporary scheduling order
What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.
91 FR 37822 · Federal Register FR Doc. 2026-12654
Temporary scheduling order
What changedDEA placed the substance temporarily in Schedule I.
Temporary order following the notice of intent; the order cites 91 FR 37822.
91 FR 52013 · Federal Register FR Doc. 2026-16413
Correcting amendment to the order above
Corrects the August 12, 2026 order, cited as 91 FR 52013.
The correction's official title omits “Temporary.” The placement it corrects remains temporary.
91 FR 64617 · Federal Register FR Doc. 2026-20748
How to cite
Behavioral Wire. “O-desmethyltramadol (O-DSMT): temporary Schedule I placement” (DEA-1641). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1641
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Current status Temporary Schedule I placement remains in effect through August 27, 2028, unless extended or replaced through subsequent action.
Summary
On July 1, 2026 DEA announced its intent to issue a temporary order placing four substances in Schedule I: 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine and spirochlorphine. DEA issued the temporary order August 27, 2026, effective August 27, 2026 until August 27, 2028.
Regulatory sequence, oldest first
Notice of intent to issue a temporary scheduling order
What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.
No scheduling effective date is shown for this event; scheduling begins only with the order.
91 FR 39940 · Federal Register FR Doc. 2026-13364
Temporary scheduling order
What changedDEA placed the four substances temporarily in Schedule I.
Temporary order following the notice of intent; the order cites 91 FR 39940.
91 FR 55252 · Federal Register FR Doc. 2026-17531
How to cite
Behavioral Wire. “5,6-Dichloro brorphine and related substances: temporary Schedule I placement” (DEA-1665). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1665
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Current status Temporary Schedule I placement remains in effect through May 22, 2028, unless extended or replaced through subsequent action.
Summary
On January 20, 2026 DEA announced its intent to issue a temporary order placing 2-fluorodeschloroketamine (2-FDCK) in Schedule I. DEA issued the temporary order May 22, 2026, effective May 22, 2026 until May 22, 2028.
Regulatory sequence, oldest first
Notice of intent to issue a temporary scheduling order
What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.
91 FR 2323 · Federal Register FR Doc. 2026-00954
Temporary scheduling order
What changedDEA placed the substance temporarily in Schedule I.
Temporary order following the notice of intent; the order cites 91 FR 2323.
91 FR 30204 · Federal Register FR Doc. 2026-10253
How to cite
Behavioral Wire. “2-Fluorodeschloroketamine (2-FDCK): temporary Schedule I placement” (DEA-1442). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1442
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Current status Temporary Schedule I placement remains in effect through March 16, 2028, unless extended or replaced through subsequent action.
Summary
On December 15, 2025 DEA announced its intent to issue a temporary order placing bromazolam in Schedule I. It issued the temporary order March 16, 2026, effective March 16, 2026 until March 16, 2028. A correcting amendment published June 24, 2026 replaced an invalid chemical name in the CFR listing with the valid one; it is not a new scheduling decision.
Regulatory sequence, oldest first
Notification of intent to issue a temporary scheduling order
What changedNo legal change yet; DEA announced its intent to issue a temporary scheduling order.
90 FR 57924 · Federal Register FR Doc. 2025-22763
Temporary scheduling order
What changedDEA placed the substance temporarily in Schedule I.
Temporary order following the notice of intent; the order cites 90 FR 57924.
91 FR 12504 · Federal Register FR Doc. 2026-05064
Correcting amendment to the order above
Corrects the March 16, 2026 order, cited as 91 FR 12504.
The correction's official title omits “Temporary.” The placement it corrects remains temporary.
91 FR 37821 · Federal Register FR Doc. 2026-12653
How to cite
Behavioral Wire. “Bromazolam: temporary Schedule I placement” (DEA-1420). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1420
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Current status The final rule is in effect since July 9, 2026.
Summary
In November 2020 DEA issued an interim final rule amending its regulations to make them consistent with the 2018 SUPPORT Act. In June 2026 DEA published a final rule, effective July 9, 2026. It adopts the provisions of the interim final rule that are still applicable as final, with minor changes. It removes provisions the interim rule had based on statutes since repealed, and it includes provisions tied to the Restoring Hope for Mental Health and Well-Being Act of 2022.
Official titleImplementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment.
“Implementation” is part of the government's title; it is not a Behavioral Wire claim of operational implementation tracking.
Regulatory sequence, oldest first
Interim final rule with request for comments
What changedDEA amended its regulations to make them consistent with the 2018 SUPPORT Act, effective on an interim basis with comments invited.
The document's stated effective date precedes its Federal Register publication date.
85 FR 69153 · Federal Register FR Doc. 2020-23813
Final rule
What changedDEA adopted the still-applicable interim provisions as final, with minor changes; removed provisions based on repealed statutes; and included provisions tied to the Restoring Hope Act.
Finalizes in part the interim final rule; the final rule cites it as 85 FR 69153.
91 FR 34754 · Federal Register FR Doc. 2026-11526
The final rule took legal effect.
No provision-level description beyond the verified summary is asserted here. Readers should consult the linked Federal Register text.
Established by 91 FR 34754 · Federal Register FR Doc. 2026-11526
How to cite
Behavioral Wire. “SUPPORT Act regulations: dispensing and administering controlled substances for medication-assisted treatment” (DEA-499). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-499
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Current status Proposal stage. The comment period closed August 10, 2026; no final rule was located as of October 31, 2026.
ImportantPrecursor chemical regulation, not scheduling of a controlled substance.
Summary
This record concerns regulation of precursor (List I) chemicals under the Controlled Substances Act. It is not scheduling of a controlled substance. In October 2024 DEA published an advance notice asking for information on uses of phenethyl bromide before deciding whether to propose listing it. In July 2026 DEA proposed designating phenethyl halides as List I chemicals, a wider group than phenethyl bromide alone.
Regulatory sequence, oldest first
Advance notice of proposed rulemaking: Possible Control of Phenethyl Bromide as a List I Chemical
Scope: phenethyl bromide
What changedNo legal change; DEA requested information on the uses of phenethyl bromide before deciding whether to propose listing it.
89 FR 85459 · Federal Register FR Doc. 2024-24616
Notice of proposed rulemaking: Designation of Phenethyl Halides as List I Chemicals
Scope: phenethyl halides
What changedDEA opened a proposed rule; no final action has been located. If finalized, it would subject handlers of phenethyl halides to the chemical regulatory provisions of the Controlled Substances Act.
Cites the 2024 advance notice, 89 FR 85459.
91 FR 42392 · Federal Register FR Doc. 2026-13825
How to cite
Behavioral Wire. “Phenethyl bromide / phenethyl halides: proposed List I chemical designation” (DEA-1282). Regulation & Policy, Regulatory Decision & Effective-Date Record. Status as of October 31, 2026. https://behavioralwire.com/intelligence#dea-1282
The status date is when this record was last checked against the Federal Register. It is not the publication or effective date of the rule: those are shown in the record above, and the linked Federal Register text controls.
Temporary-order end dates reflect the Federal Register action in force as of the record date. Temporary scheduling periods may be extended through subsequent agency action where authorized by law.